Ocular Surface Features in Patients with Parkinson Disease on and off Treatment: A Narrative Review
Parkinson disease (PD) is a progressive, neurodegenerative disease of the central nervous system. Visual disturbance is one of the most frequent nonmotor abnormalities referred to by patients suffering from PD at early stages. Furthermore, ocular surface alterations including mainly dry eye and blink reduction represent another common finding in patients with PD. Tears of PD patients show specific alterations related to protein composition, and in vivo confocal microscopy has demonstrated profound changes in different corneal layers in this setting. These changes can be attributed not only to the disease itself, but also to the medications used for its management. In particular, signs of corneal toxicity, both at epithelial and endothelial level, are well described in the literature in PD patients receiving amantadine. Management of PD patients from the ophthalmologist’s side requires knowledge of the common, but often underdiagnosed, ocular surface alterations as well as of the signs of drug toxicity. Furthermore, ocular surface biomarkers can be useful for the early diagnosis of PD as well as for monitoring the degree of neural degeneration over time..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Life - 12(2022), 12, p 2141 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Matilde Buzzi [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Amantadine |
|---|
| doi: |
10.3390/life12122141 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ083044124 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ083044124 | ||
| 003 | DE-627 | ||
| 005 | 20240414150707.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230311s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/life12122141 |2 doi | |
| 035 | |a (DE-627)DOAJ083044124 | ||
| 035 | |a (DE-599)DOAJa27d8c47a9374eb8ae01de6782306a7e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Matilde Buzzi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ocular Surface Features in Patients with Parkinson Disease on and off Treatment: A Narrative Review |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Parkinson disease (PD) is a progressive, neurodegenerative disease of the central nervous system. Visual disturbance is one of the most frequent nonmotor abnormalities referred to by patients suffering from PD at early stages. Furthermore, ocular surface alterations including mainly dry eye and blink reduction represent another common finding in patients with PD. Tears of PD patients show specific alterations related to protein composition, and in vivo confocal microscopy has demonstrated profound changes in different corneal layers in this setting. These changes can be attributed not only to the disease itself, but also to the medications used for its management. In particular, signs of corneal toxicity, both at epithelial and endothelial level, are well described in the literature in PD patients receiving amantadine. Management of PD patients from the ophthalmologist’s side requires knowledge of the common, but often underdiagnosed, ocular surface alterations as well as of the signs of drug toxicity. Furthermore, ocular surface biomarkers can be useful for the early diagnosis of PD as well as for monitoring the degree of neural degeneration over time. | ||
| 650 | 4 | |a Parkinson’s disease | |
| 650 | 4 | |a ocular surface | |
| 650 | 4 | |a cornea | |
| 650 | 4 | |a tears | |
| 650 | 4 | |a dry eye | |
| 650 | 4 | |a amantadine | |
| 653 | 0 | |a Science | |
| 653 | 0 | |a Q | |
| 700 | 0 | |a Giuseppe Giannaccare |e verfasserin |4 aut | |
| 700 | 0 | |a Michela Cennamo |e verfasserin |4 aut | |
| 700 | 0 | |a Federico Bernabei |e verfasserin |4 aut | |
| 700 | 0 | |a Pierre-Raphael Rothschild |e verfasserin |4 aut | |
| 700 | 0 | |a Aldo Vagge |e verfasserin |4 aut | |
| 700 | 0 | |a Vincenzo Scorcia |e verfasserin |4 aut | |
| 700 | 0 | |a Rita Mencucci |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Life |d MDPI AG, 2012 |g 12(2022), 12, p 2141 |w (DE-627)DOAJ000123765 |x 20751729 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:12, p 2141 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/life12122141 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/a27d8c47a9374eb8ae01de6782306a7e |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/2075-1729/12/12/2141 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2075-1729 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 12, p 2141 | ||